Life after abciximab; what's next for intracoronary thrombus?

被引：1
作者：
McGhie, D. [1 ]
Amos, D. [1 ]
Elder, A. [1 ]
Brieger, D. [2 ]
Lowe, H. C. [1 ,2 ]
机构：
[1] Orange Base Hosp, Dept Cardiol, Orange, NSW 2800, Australia
[2] Concord Repatriat Gen Hosp, Dept Cardiol, Concord, NSW 2139, Australia
来源：
JOURNAL OF THROMBOSIS AND THROMBOLYSIS | 2020年 / 49卷 / 01期
关键词：
Abciximab; Tirofiban; Coronary; Stent; Thrombus; PERCUTANEOUS CORONARY INTERVENTION; ELEVATION MYOCARDIAL-INFARCTION; PRASUGREL; TIROFIBAN;
D O I：
10.1007/s11239-019-01977-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A case is described in which the short-acting glycoprotein IIb/IIIa receptor antagonist tirofiban was used in combination with heparin, aspirin and prasugrel to successfully treat extensive intracoronary thrombus in a delayed presentation STEMI, illustrating the utility of this approach.
引用
收藏
页码：138 / 140
页数：3
相关论文
共 9 条
  • [1] National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016
    Chew, Derek P.
    Scott, Ian A.
    Cullen, Louise
    French, John K.
    Briffa, Tom G.
    Tideman, Philip A.
    Woodruffe, Stephen
    Kerr, Alistair
    Branagan, Maree
    Aylward, Philip E. G.
    [J]. HEART LUNG AND CIRCULATION, 2016, 25 (09) : 895 - 951
  • [2] Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry
    De la Torre Hernandez, Jose M.
    Sadaba Sagredo, Mario
    Telleria Arrieta, Miren
    Gimeno de Carlos, Federico
    Sanchez Lacuesta, Elena
    Bullones Ramirez, Juan A.
    Pineda Rocamora, Javier
    Martin Yuste, Victoria
    Garcia Camarero, Tamara
    Larman, Mariano
    Rumoroso, Jose R.
    [J]. BMC CARDIOVASCULAR DISORDERS, 2017, 17
  • [3] Prasugrel versus clopidogrel in acute coronary syndromes treated with PCI: Effects on clinical outcome according to culprit artery location
    De Servi, Stefano
    Goedicke, Jochen
    Ferlini, Marco
    Palmerini, Tullio
    Syvanne, Mikko
    Montalescot, Gilles
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 223 : 632 - 638
  • [4] Hanrath P, 1997, CIRCULATION, V96, P1445
  • [5] Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
    Montalescot, Gilles
    Wiviott, Stephen D.
    Brounwald, Eugene
    Murphy, Sabina A.
    Gibson, C. Michael
    McCabe, Carolyn H.
    Antman, Elliott M.
    [J]. LANCET, 2009, 373 (9665) : 723 - 731
  • [6] Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention Multicenter Randomized PRAGUE-18 Study
    Motovska, Zuzana
    Hlinomaz, Ota
    Miklik, Roman
    Hromadka, Milan
    Varvarovsky, Ivo
    Dusek, Jaroslav
    Knot, Jiri
    Jarkovsky, Jiri
    Kala, Petr
    Rokyta, Richard
    Tousek, Frantisek
    Kramarikova, Petra
    Majtan, Bohumil
    Simek, Stanislav
    Branny, Marian
    Mrozek, Jan
    Cervinka, Pavel
    Ostransky, Jiri
    Widimsky, Petr
    [J]. CIRCULATION, 2016, 134 (21) : 1603 - +
  • [7] Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting
    Neumann, FJ
    Hochholzer, W
    Pogatsa-Murray, G
    Schömig, A
    Gawaz, M
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (05) : 1323 - 1328
  • [8] Abciximab improves 6-month clinical outcome after rescue coronary angioplasty
    Petronio, AS
    Musumeci, G
    Limbruno, U
    De Carlo, M
    Baglini, R
    Paterni, G
    Delle Donne, MG
    Caravelli, P
    Nardi, C
    Mariani, M
    [J]. AMERICAN HEART JOURNAL, 2002, 143 (02) : 334 - 341
  • [9] Wang HL, 2014, EUR REV MED PHARMACO, V18, P3690
1